Navigation Links
Bionovo Announces First Quarter 2009 Highlights and Financial Results
Date:5/7/2009

EMERYVILLE, Calif., May 7 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced first quarter highlights and financial results for the three months ended March 31, 2009.

Company Highlights

  • Bionovo presented data on a preclinical anti-cancer drug candidate, BN108, at the American Association of Cancer Research (AACR) conference in April. TspA3 has been identified as an active compound of BN108 that is responsible for BN108's selective cytotoxicity. BN108 and TspA3 induce apoptosis through rapid inactivation of AKT and mTOR kinases in breast cancer cells but not in normal cells.
  • Two additional members joined Bionovo's Scientific Advisory Board, Jan-Ake Gustafsson and Bert W. O'Malley.
  • The Company continues to work towards satisfying the FDA's requests for clarification of the manufacturing and analytical strategy to be used in ensuring the consistency of its drug products.
  • The Company continues to pursue a wide variety of funding options including government grants, partnering, and debt and equity offerings.

First Quarter Results

Total operating expenses for the three months ending March 31, 2009 were $4.6 million compared to $4.2 million for the same period in 2008. Total operating expenses for the first quarter included one-time expenses associated with the relocation of the Company's headquarters, the purchase of raw materials for manufacturing purposes throughout the year, and severance costs. The Company expects operating expenses to decrease in the second quarter.

The Company reported a net loss for the three months ended March 31, 2009 of $4.7 million, or $0.06 per share, compared with a net loss of $3.9 million, or $0.05 per share,
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
2. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
3. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
4. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
5. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
8. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
9. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
10. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
11. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Idaho , Jan. 23, 2015  Now available for ... No. 7,849,611) support that prevents ankle sprains by cushioning ... brace, it fits securely around the outside of any ... mobility & comfort while still offering protection against sprains. ...
(Date:1/23/2015)... , Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), ... equipment for all forms of sports, including extreme motor ... brace, announced today that the UISP Lega Motociclismo Lombardia, ... all riders to wear a neck brace during its ...
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... N.J., May 26, 2011 Johnson & Johnson (NYSE: ... its Pharmaceuticals business at a meeting with the investment ... and pharmaceuticals segment will review how the business plans ... needs and outpace pharmaceutical market growth with an optimized ...
... Pharmaceuticals, Inc. (NASDAQ: AMLN ) ("Amylin" or "the ... the Southern District of California issued a temporary restraining order ... ) ("Lilly") relating to its litigation with respect to the ... District Court restrained Lilly from proceeding with its plans to ...
Cached Medicine Technology:Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 2Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 3Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 4Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 5Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly 2Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly 3Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly 4
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... 22, 2015 As interest in the value ... gains momentum worldwide, Rev. Eric J. Hall , president ... (HCCN), will be the keynote speaker on January 27 ... public health system. , The conference, “Hope and Resilience: Innovative ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list of ... . , Some types of vehicles cannot be covered under ... blog post to see if their vehicle qualifies for auto insurance ... of the cars that cannot be covered by a plan. Clients ...
(Date:1/22/2015)... 2015 Step into a macabre world ... Museum of Virginia. Wicked Plants, the Museum’s latest featured ... 75 poisonous, carnivorous and diabolical plants inside of a ... uncover the biochemical, physical and neurological processes between botanicals ...
(Date:12/26/2014)... The US represents the largest market for CRC ... forecast estimates that sales of branded therapies were $2.23 billion. ... high incidence of the disease, high drug treatment rate, and ... Increased sales of CRC therapies over the forecast period will ...
Breaking Medicine News(10 mins):Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... Laboratories, L.P.,today announced that the U.S. Food and Drug ... vitamin D3 product for the,treatment of mild-to-moderate plaque psoriasis ... a chronic skin disorder that affects 2 to 3 ... red, scaly patches of skin and,caused by an abnormally ...
... To mark American Heart,Month, deCODE genetics (Nasdaq: DCGN ... will offer its deCODEme Cardio Scan(TM), the unique new ... of heart,attack, stroke and atrial fibrillation, intracranial and abdominal ... of,$100. , On Thursday, February ...
... 3 NxStage Medical, Inc. (Nasdaq: NXTM ), ... to release its financial results for the fourth quarter and ... 2009 before the opening of the financial markets.NxStage will also ... Thursday, March 12, 2009 to discuss its fourth quarter and ...
... 3 The Albert and Mary Lasker Foundation ... , the immediate past director of the National Institutes of ... Directors."We are delighted that Dr. Zerhouni has agreed to join ... , President of the Lasker Foundation. "The Lasker Foundation is ...
... to Chief Marketing Officer and PACS Industry Veteran ... ManagerWASHINGTON, Feb. 3 Compressus, Inc., leaders in ... team with the promotion of Janine Broda to ... Shawn Gibbons as vice president and general manager ...
... The Female Health Company (NYSE Alternext: FHC) today ... to discuss its operating results for the first quarter ... Tuesday, February 10, 2009. The Company plans to ... day. Shareholders and other interested parties may participate in ...
Cached Medicine News:Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 2Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 3Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 4Health News:deCODEme(TM) Takes on Heart Disease in February 2Health News:deCODEme(TM) Takes on Heart Disease in February 3Health News:deCODEme(TM) Takes on Heart Disease in February 4Health News:deCODEme(TM) Takes on Heart Disease in February 5Health News:NxStage to Report Fourth Quarter and Full Year 2008 Financial Results 2Health News:Lasker Foundation Welcomes Elias Zerhouni to Board of Directors 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 3Health News:The Female Health Company Schedules First Quarter Conference Call for February 10, 2009 2
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
... 10% Povidone Iodine USP, 1% available Iodine, ... prep, Povidone Iodine Gel helps to minimize ... patient, thus reducing the chance of patient ... a one step gel for venipuncture site ...
... Gel is a viscous antimicrobial that contains ... for broad-spectrum germicidal action. As a preoperative ... minimize the pooling of prepping solutions under ... patient burns. Povidone Iodine Topical Gel is ...
... Povidone Iodine Prep Solution is appropriate ... paint, wet soak or spray); disinfecting ... antiseptic treatment of lacerations and abrasions. ... anti-infective agent in hospital and office ...
Medicine Products: